WO2001089450A3 - Treating musculoskeletal disorders using lp85 and analogs thereof - Google Patents

Treating musculoskeletal disorders using lp85 and analogs thereof Download PDF

Info

Publication number
WO2001089450A3
WO2001089450A3 PCT/US2001/011755 US0111755W WO0189450A3 WO 2001089450 A3 WO2001089450 A3 WO 2001089450A3 US 0111755 W US0111755 W US 0111755W WO 0189450 A3 WO0189450 A3 WO 0189450A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogs
musculoskeletal disorders
treating musculoskeletal
treating
connective tissues
Prior art date
Application number
PCT/US2001/011755
Other languages
French (fr)
Other versions
WO2001089450A2 (en
Inventor
John Michael Beals
Patricia Ann Gonzalez-Dewhitt
Lisa Janine Hammond
Jirong Lu
Songqing Na
Eric Wen Su
Derrick Ryan Witcher
Victor John Wroblewski
Original Assignee
Lilly Co Eli
John Michael Beals
Gonzalez Dewhitt Patricia Ann
Lisa Janine Hammond
Jirong Lu
Songqing Na
Eric Wen Su
Derrick Ryan Witcher
Victor John Wroblewski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, John Michael Beals, Gonzalez Dewhitt Patricia Ann, Lisa Janine Hammond, Jirong Lu, Songqing Na, Eric Wen Su, Derrick Ryan Witcher, Victor John Wroblewski filed Critical Lilly Co Eli
Priority to AU2001272902A priority Critical patent/AU2001272902A1/en
Publication of WO2001089450A2 publication Critical patent/WO2001089450A2/en
Publication of WO2001089450A3 publication Critical patent/WO2001089450A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides methods for treating or preventing osteoporosis, osteopenia, sarcopenia, arthritis, tissue atrophy, wound healing, traumatized connective tissues, grafted connective tissues, and/or transplanted organs in a mammal which comprise the administration of a therapeutically effective amount of a pharmaceutical composition comprising a LP85 polypeptide or LP85 analog.
PCT/US2001/011755 2000-05-19 2001-05-08 Treating musculoskeletal disorders using lp85 and analogs thereof WO2001089450A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001272902A AU2001272902A1 (en) 2000-05-19 2001-05-08 Treating musculoskeletal disorders using lp85 and analogs thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US20542400P 2000-05-19 2000-05-19
US60/205,424 2000-05-19
US26107601P 2001-01-11 2001-01-11
US26107101P 2001-01-11 2001-01-11
US60/261,071 2001-01-11
US60/261,076 2001-01-11

Publications (2)

Publication Number Publication Date
WO2001089450A2 WO2001089450A2 (en) 2001-11-29
WO2001089450A3 true WO2001089450A3 (en) 2002-05-02

Family

ID=27394788

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/011755 WO2001089450A2 (en) 2000-05-19 2001-05-08 Treating musculoskeletal disorders using lp85 and analogs thereof

Country Status (2)

Country Link
AU (1) AU2001272902A1 (en)
WO (1) WO2001089450A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6663870B2 (en) 1998-12-07 2003-12-16 Zymogenetics, Inc. Methods for promoting growth of bone using zvegf3
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
AU2002248237A1 (en) 2000-10-30 2002-08-12 Zymogenetics, Inc. Compositions and methods for improving kidney function
US7135174B2 (en) * 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027879A1 (en) * 1998-11-10 2000-05-18 Ludwig Institute For Cancer Research Platelet-derived growth factor d, dna coding therefor, and uses thereof
WO2000066736A1 (en) * 1999-05-03 2000-11-09 Zymogenetics, Inc. Growth factor homolog zvegf4
WO2001000878A2 (en) * 1999-06-30 2001-01-04 Millennium Pharmaceuticals, Inc. A novel vascular endothelial growth factor family member and uses thereof
WO2001025437A2 (en) * 1999-10-07 2001-04-12 Curagen Corporation Growth factor polypeptides and nucleic acids encoding same
WO2001057083A1 (en) * 2000-02-04 2001-08-09 Zymogenetics, Inc. Methods for promoting growth of bone, ligament, and cartilage using zvegf4

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027879A1 (en) * 1998-11-10 2000-05-18 Ludwig Institute For Cancer Research Platelet-derived growth factor d, dna coding therefor, and uses thereof
WO2000066736A1 (en) * 1999-05-03 2000-11-09 Zymogenetics, Inc. Growth factor homolog zvegf4
WO2001000878A2 (en) * 1999-06-30 2001-01-04 Millennium Pharmaceuticals, Inc. A novel vascular endothelial growth factor family member and uses thereof
WO2001025437A2 (en) * 1999-10-07 2001-04-12 Curagen Corporation Growth factor polypeptides and nucleic acids encoding same
WO2001057083A1 (en) * 2000-02-04 2001-08-09 Zymogenetics, Inc. Methods for promoting growth of bone, ligament, and cartilage using zvegf4

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERGSTEN E ET AL: "PDGF-D IS A SPECIFIC, PROTEASE-ACTIVATED LIGAND FOR THE PDGF BETA-RECEPTOR", NATURE CELL BIOLOGY, MACMILLAN PUBLISHERS, GB, vol. 3, 11 April 2001 (2001-04-11), pages 512 - 516, XP002941175, ISSN: 1465-7392 *
LAROCHELLE WILLIAM J ET AL: "PDGF-D, a new protease-activated growth factor.", NATURE CELL BIOLOGY, vol. 3, no. 5, May 2001 (2001-05-01), pages 517 - 521, XP001053430, ISSN: 1465-7392 *
MIDY V & PLOUËT J: "Vasculotropin/Vascular Endothelial Growth Factor induces differentiation in cultured osteoblasts", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 199, no. 1, 28 February 1994 (1994-02-28), pages 380 - 386, XP002148857, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2001089450A2 (en) 2001-11-29
AU2001272902A1 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
EP2123293A3 (en) Peptide YY and petide YY agonists for treatment of metabolic disorders
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
CA2426703A1 (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
IS8807A (en) Use of daptomycin and the pharmaceutical compositions containing it
WO2001082971A3 (en) Cyclodextrin containing glycopeptide antibiotic compositions
FR06C0032I2 (en) PROTEIN FORMULATIONS
BR0008509A (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
WO2005072277A3 (en) Amidated parathyroid hormone fragments and uses thereof
WO2003082196A3 (en) Combination therapy using trefoil peptides
WO2001030333A3 (en) Tissue factor antagonists and methods of use thereof
WO2002059143A3 (en) Therapeutic peptides for demyelinating conditions
ID18079A (en) PHARMACEUTICAL COMPOSITION THAT CONTAINS FASTEST OSTEOGENESIS
TW200503689A (en) Pharmaceutical compositions of atorvastatin
NO20021625L (en) Synergistic combinations of an NK1 receptor antagonist and a GABA structural analogue
WO2003032910A3 (en) Carbinols for the treatment of neuropathic dysfunction
WO2001089450A3 (en) Treating musculoskeletal disorders using lp85 and analogs thereof
CA2433785A1 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
EP1080724A4 (en) Mtp activity-lowering compositions
WO2003099849A3 (en) Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
WO2001032197A3 (en) Methods of using lp8, a pdgf-related protein, to treat musculoskeletal disorders
WO1994016723A3 (en) Wound healing composition
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
GB9516967D0 (en) Pharmaceutical composition
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
WO2003103614A3 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10258557

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP